Aim-To assess the sensitivity of activated partial thromboplastin time (APTT) reagents for monitoring heparin dosage using data from the UK National External Quality Assessment Scheme (NEQAS) for blood coagulation. Methods-Data were reviewed from four surveys using samples prepared by addition ofheparin to normal plasma in vitro and from two surveys in which samples were prepared using plasma from patients receiving heparin therapy (ex vivo samples). responsiveness to heparin'7-10 and this is influenced further by whether the heparin is added in vitro or whether it is assessed in samples from patients receiving heparin.2 11-13
Many centres use the APTT and a therapeutic range calculated by the APTT ratio (test/normal APTT) of 1 5-2-5 irrespective of reagent. However, APTT reagents vary in their responsiveness to heparin'7-10 and this is influenced further by whether the heparin is added in vitro or whether it is assessed in samples from patients receiving heparin.2 [11] [12] [13] The assessment of laboratory control of heparin therapy is an important component of the UK National Quality Assessment Scheme (NEQAS) for blood coagulation. In this scheme lyophilised plasma samples are distributed to over 420 laboratories carrying out tests for assessing heparin dosage. Participants are requested to assess heparin dosage using their routine method. The APTT is used by 98% of participating laboratories for this purpose, although a considerable number of reagents and end point detection methods are in use. Statistical analysis of data returned allows comparisons to be made between different reagents.
Samples distributed through the College of American Pathologists,'3 and through the UK NEQAS have traditionally been prepared by the addition of heparin to normal plasma in vitro. In recent UK NEQAS surveys, however, samples for heparin dosage assessment have been prepared using samples from patients receiving heparin. In this report we have compared the responsiveness of APTT reagents for measuring heparin dosage in the two types of samples (in vitro and ex vivo) tested by a large number of laboratories.
Methods

ADDITION OF HEPARIN TO NORMAL PLASMA IN VITRO
Plasma was collected from normal subjects as described elsewhere. 14 About 600 ml blood was collected over 45 minutes into citrate phosphate dextrose anticoagulant using a Haemonetics Ultralight instrument. Blood was then centrifuged twice at 2500 x g at 40C for 30 minutes and stored in bulk at -40°C for up to 12 weeks. The plasma was then thawed and buffered with 0 034 M hydroxyethylpiperazine ethane sulphonic acid. Unfractionated sodium heparin was then added prior to lyophilisation in 0 5 ml aliquots for six days. These lyophilised samples were then stored at -20°C for no longer than 12 The levels of clotting factors relevant to the APTT (factors II, V, VIII:C, IX, X, XI, XII, and fibrinogen) were determined in the lyophilised samples distributed in each of the six surveys. Factors II, V and X assays were performed using rabbit brain thromboplastin (PT Fib HSPlus Instrumentation Laboratory, Warrington, UK). One stage assays of factors VIII:C, IX, XI, and XII were performed using Kaolin/ platelet substitute (Diagnostic Reagents, Tuame, UK) with five minute activation and 0-025 M calcium chloride. All assays were carried out on the Automated Coagulation Laboratory (ACL) instrument, using three dilutions of test or standard plasma and human deficient plasma. Assays were calibrated using the following standard plasmas: 19th British Standard for factor VIII:C; 6th British Standard for Blood Coagulation Factors (IX); snap frozen pooled plasma derived from 25 normal donors and stored at -70°C for factors II, V, X, XI, and XII. Fibrinogen concentration was determined by Clauss's'5 method. The heparin concentration was determined using a clotting anti-Xa assay calibrated with the 4th International Standard for unfractionated heparin as described previously. ' 
Reagents were ranked by heparin sensitivity based on the mean results in four surveys using plasma to which heparin has been added in vitro and the mean of two surveys using pooled samples from patients receiving heparin (table  2) . The relation between reagents with respect to heparin sensitivity was different for the two types of sample-for example, reagent ML was associated with ratios 51% higher than IL for samples heparinised in vitro, and 3% lower than IL for pooled ex vivo samples. Ratios obtained by users of DB were 13% higher than ratios with OA in samples heparinised in vitro, and 21 % lower than OA for samples from patients receiving heparin. Reagent DB ranked third and seventh (out of nine) for the two types of sample. Reagent IL ranked sixth and second. A number of other such discrepancies were also present (table 2) .
In heparin dosage assessment exercises UK NEQAS participants are provided with brief clinical details and are asked to interpret their result as "no heparin detected", "inadequate", "adequate", or "overdose" of heparin. For survey 82, in which the sample distributed was a plasma pool from patients receiving heparin, 33 (94%) of the 35 users of reagent B (median ratio 1 30) regarded the sample as inadequate with respect to the local therapeutic range, whereas 126 (90%) of 140 users of IL reagent (median ratio 1 93) considered the heparin dosage to be adequate. The median APTT 
CLOTTING FACTOR AND HEPARIN CONCENTRATIONS IN SURVEY SAMPLES
A summary of clotting factor and heparin concentrations determined by an anti-Xa method is shown in table 4. Concentrations of factor VIII:C and fibrinogen were more than twofold higher in pooled samples from patients receiving heparin (surveys 82 and 84) compared with normal plasma samples heparinised in vitro (surveys 73-79). The concentrations of other clotting factors were similar in the two groups of samples. Mean heparin concentrations (anti-Xa activity) were similar in the two sample types (table 4).
Discussion
Unfractionated intravenous heparin is widely used for the treatment of venous thromboembolism. Heparin dosage monitoring is usually achieved through an APTT test and with this monitoring system, a number of studies have demonstrated a correlation between inadequate heparinisation and recurrence of thrombosis."'67 As a direct consequence of these observations most laboratories have adopted a therapeutic range of 1. 5-2T5. However, APTT reagents vary in their sensitivity to heparin and the underlying rationale for this uniform approach to monitoring of heparin dosage, irrespective of reagent, seems to be misplaced.
NEQAS is an established method for assessing not only individual laboratory performance with respect to a single analyte, but also differences in reagent performance. We therefore analysed UK NEQAS results obtained with different reagents using material prepared by heparinisation of normal plasma in vitro and also by pooled ex vivo samples from patients receiving heparin as the response of APTT methods to the two sample types may differ.2'11-13
For both in vitro and ex vivo samples notable differences between APTT reagents with respect to their response to heparin were observed. For example, in one survey (84), in which ex vivo samples were used, the median ratio obtained by users of one reagent was 1-37 compared with 2-36 for users of another. This indicates that a uniform therapeutic range of 1 5-2-5 may not be appropriate. A statistical comparison between the least and most responsive ofthe APTT reagents in each ofthe six surveys revealed highly significant differences (p<0000 1 APTTs determined with reagents ML and IL.
In the study by Kitchen and Preston'0 the use of the ACL with reagent IL was not associated with differences between APTT ratios when compared with the manual technique, whereas use of this instrument in conjunction with reagent ML led to a significant increase in APTT ratios (from a mean of 2-3 to a mean of 3.1). Individual fresh samples from patients receiving heparin were used in that study.'0 Some of the reagents described in the present study (ML, IL, DB, DK, B, and M) were the subject of a study comparing APTT ratios (patient:mean normal APTT) with heparin concentrations'0 in ex vivo samples from patients receiving heparin. In this study the ranking of these six reagents by sensitivity to heparin, based on the mean of 21 individual plasma samples and using the manual technique, was as follows: IL, ML, M, DB, DK, and B. This ranking related to fresh samples (analysed within two hours of collection and with varied order of testing with different reagents) from patients receiving full dose intravenous sodium heparin and with an international normalised ratio less than 1-3. This order is identical with that obtained by NEQAS participants in surveys 82 and 84 using lyophilised pooled ex vivo samples, but is different to the ranking obtained by NEQAS participants for in vitro samples (as follows: ML, DB, M, IL, B, and DK). This suggests that pooled ex vivo samples are more appropriate than the addition ofheparin to normal plasma in vitro as the relation between reagents is maintained.
Differences between in vitro and ex vivo samples with respect to the sensitivity of APTT reagents to heparin have been described in both single centre9"0 and multicentre'3 studies of in vitro samples. The UK NEQAS data from six surveys, each including around 400 laboratories, indicate notable differences between reagents with respect to their response to heparin and that the use of samples collected from patients receiving heparin is more appropriate than the addition of heparin to normal plasma. The importance of reagent differences is emphasised by the clinical conclusions based on results of one survey (using ex vivo samples), in which 94% ofusers ofone reagent considered the heparin dosage to be inadequate, whereas 90% of users of another reagent regarded it as adequate.
Results obtained by this large series oflaboratories clearly indicate that APTT reagents vary noticeably with respect to their response to heparin, suggesting that reagent specific therapeutic ranges are required, and that samples prepared by the additon of heparin to normal plasma in vitro for this purpose can be misleading and should not be used.
